Macrocure (MCUR) Misses Q4 EPS by 10c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Macrocure Ltd. Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results
March 17, 2015 4:05 PM EDTCompany announces anticipated timeline for DFU Phase III clinical trial results
Company accelerates timelines for VLU Phase III clinical trial results
Conference call and webcast scheduled for March 18, 2015 at 9:00 am Eastern Time
PETACH TIKVA, Israel, March 17, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. ("Macrocure" or "the Company") (Nasdaq: MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014.
Recent... More
